Avid Bioservices (CDMO) Tops Q4 EPS by 12c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Avid Bioservices (CDMO) PT Raised to $6 at H.C. Wainwright
July 17, 2018 10:22 AM EDTH.C. Wainwright raised its price target on Avid Bioservices (NASDAQ: CDMO) to $6.00 (from $5.00) while maintaining a Buy rating.
Analyst Joseph Pantginis commented, "Yesterday, CDMO reported F4Q18 and FY18 ended April 30, 2018, posting EPS of $0.03 and ($0.56), respectively, compared with our estimate of ($0.23) and ($0.87) and consensus of ($0.15) and... More
